NCT05552612Completed
Health-related Quality of Life and Long COVID
Quality-of-life in Patients With Long COVID: Harnessing the Scale of Big Data to Quantify the Health and Economic Costs
Source: ClinicalTrials.gov · Last updated 28 Mar 2024
Brief summary (registry, in English)
Background: Long COVID is estimated to affect 1.7 million people in the UK. One way of assessing the impact of long COVID is to measure quality-of-life through a standard questionnaire, which can then be used to understand the costs of long COVID to the NHS and wider economy. The impact of long COVID on these measures is not currently known. It is important to understand who is worst affected by long COVID and the cost to the National Health Service (NHS), so that strategies like booster vaccines can be prioritised to the right people. Aim: OpenPROMPT aims to understand the impact of long COVID on quality-of-life in adults in English primary care. Methods: We will ask people to participate in the study by downloading a smartphone app, and completing a series of questionnaires held within the app. Questionnaires will ask about quality of life, productivity and symptoms of long COVID. Participants will be asked to fill in the questionnaires once a month, for four months. Electronic reminders will be sent to participants to ask them to complete the questionnaires, which will take roughly 15 minutes to complete each month. Participants will also be asked to give consent for linkage of their questionnaire responses to their existing health records. The results will tell us if long COVID has different quality-of-life and economic impacts among people of different ages, ethnicities, geographic regions, or because of any underlying health conditions. These results can be converted into standardised measurements used by the NHS to measure the impact of illnesses and the cost of long COVID to health services. Impact: Together with other researchers studying long COVID, we will provide results to support long-term care, and make recommendations for prevention of long COVID in the future. At all stages we will ensure that the input of patients and the public is central to running the study and interpreting the outputs. Funding: OpenPROMPT is a collaboration between the London School of Hygiene and Tropical Medicine, the OpenSAFELY patient data platform at the University of Oxford, and TPP (which supplies clinical software to General Practices (GPs) in the UK). The project is funded by the National Institute for Health Research.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 7574 (actual)
- First submitted
- 21 Sept 2022
- Start date
- 26 Sept 2022
- Primary completion date
- 31 Oct 2023
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05552612
What you commit to
- Study type: Observational
- Participants enrolled: 7574
- From 26 Sept 2022 to the primary completion date, 31 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Patients under 18 years old;
Other
- The following patients will be excluded:
- Patients who do not have a smartphone or cannot download or log in to the Airmid app;
- Patients who cannot understand English.
Who the study is looking for
- Inclusion criteria are that the patient is aged 18 or over and can read and understand English, and can download and use the Airmid app.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| London School of Hygiene and Tropical Medicine Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.